Review Proposal - October 2010
Review of NICE Technology Appraisal Guidance No 162; Erlotinib for the treatment of non-small cell lung cancer
The planned date for review of the above guidance was June 2010.
This is the date when the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake an update of the existing guidance.
The Institute has carried out a search for information relevant to this appraisal, and believes that it is appropriate for a review of guidance to be planned into the technology appraisal work programme. The planning and scheduling of the appraisal should be based on the time that new data will become available. The final results of an ongoing study - TAILOR trial - will become available in approximately Q2 2012.
In order to be completely confident that this is appropriate, we are asking consultees and commentators with an interest in this topic, to inform us of any evidence which would suggest that an earlier review would be beneficial. We would particularly like to be made aware of timelines around on-going research etc, which might affect the scheduling of this review should we go ahead with the proposal following this consultation.
Please see appendix A for a full list of the organisations we have contacted.
- Appendix A: Matrix of stakeholders
- Appendix B: Proposal paper presented to the Institute’s Guidance Executive
This page was last updated: 07 October 2010